EURTAC

一行要約

Western (欧州) の EGFR 変異陽性未治療 NSCLC 1L における Erlotinib vs プラチナ併用化学療法の phase III。PFS HR 0.37 (9.7 vs 5.2 mo) で有意な PFS 延長を示し、non-Asian 集団における EGFR-TKI 1L benefit を初めて前向きに確認。IPASS、NEJ002、WJTOG3405 の知見を Western population に拡大した。

試験デザイン

• 対象: Stage IIIB/IV NSCLC、EGFR 変異陽性 (ex19del or L858R)、未治療、欧州 42 施設、N=174 (1:1)
• 介入群 (n=86) : Erlotinib 150 mg/day
• 対照群 (n=87) : Platinum-based doublet (Cisplatin or Carboplatin + Docetaxel or Gemcitabine)、治験医師選択、最大 4 cycles
• 層別化: EGFR 変異タイプ (ex19del vs L858R)、ECOG PS (0 vs 1)
• 主要評価項目: PFS
• Crossover: 化療群 PD 後に Erlotinib への crossover を許容 (76%)

主要結果

• PFS (primary) : HR 0.37 (95% CI 0.25–0.54, p<0.0001)、median 9.7 vs 5.2 mo
• ORR: 58% vs 15%
• OS: Median 22.9 vs 19.5 mo (HR 0.80, 95% CI 0.55–1.18, p=0.27) — crossover の影響で有意差なし
• Mutation 別: ex19del PFS HR 0.31、L858R PFS HR 0.49 — Asian trial と一貫した ex19del 優位性
• Grade ≥3 AE: Erlotinib で皮疹 13%、下痢 5%。化療群で好中球減少、貧血、悪心
• 登録難度: 欧州での EGFR 変異頻度は 約10-15% (Asian 約40-50%) であり、登録に 4 年を要した

臨床的意義

• Western population での confirmation: IPASS / NEJ002 / WJTOG3405 は主に Asian 集団。EURTAC は Western EGFR+ NSCLC で 1L TKI benefit を確認し、EGFR-TKI 1L が人種を超えた universal standard であることを証明
• Erlotinib 1L の position: Gefitinib (IPASS / NEJ002) に対し Erlotinib の 1L data を確立。後に LUX-Lung-3 (Afatinib)、FLAURA (Osimertinib) が世代を更新
• EGFR testing の global 普及: 欧米では EGFR 変異頻度が低いため検査の cost-effectiveness が議論されていたが、EURTAC の benefit magnitude が universal testing を正当化
• OS crossover の課題: 76% crossover で OS 有意差なし — この問題は EGFR-TKI 試験全般 (NEJ002、WJTOG3405、FLAURA 含む) に共通する methodological challenge

Open Questions

• Western EGFR+ の分子プロファイルの差異: Asian vs Western での co-mutation pattern (TP53、STK11、KRAS) の違いと TKI 効果への影響
• Erlotinib の現在の位置づけ: Osimertinib 1L 時代における 1st-gen TKI の residual role (resource-limited settings)
• European EGFR+ NSCLC の real-world treatment pattern: FLAURA 後の 1L TKI 選択と sequential therapy の実態

重要論文 Top 10

1. ★★★★★ Rosell et al. LancetOncol 2012 — Primary publication — Western EGFR+ 1L PFS HR 0.37
2. ★★★★ Rosell et al. LancetOncol 2012 (OS update) — OS final analysis — crossover 補正含む
3. Mok et al. (IPASS) — IPASS — EGFR selection 概念の創始
4. ★★★★★ Maemondo et al. NEnglJMed 2010 (NEJ002) — NEJ002 — Asian confirmation
5. ★★★★ Rosell et al. NEnglJMed 2009 (EGFR screening) — 欧州 lung cancer における EGFR mutation frequency

関連エンティティ・概念

• 薬剤: Erlotinib / Platinum-chemotherapy
• 関連試験: NEJ002 (Japanese 確認) / WJTOG3405 (Japanese companion) / IPASS (selection 先駆) / FLAURA (3rd-gen 1L) / LUX-Lung-3 (2nd-gen 1L)
• 関連遺伝子: EGFR (ex19del, L858R)
• ドメイン: lung-cancer-treatment

関連論文

直近 30 件のみ表示中 (関連 32 件)。 全件は MOC ページ または Obsidian (source Markdown) から辿れます。

Basic-Oncogene and genetics

• Schott et al. CancerRes 2015 — Genome medicine in cancer what’s in a name
• Du et al. MolCancer 2018 — Mechanisms of receptor tyrosine kinase activation in cancer

Clinical-Epidemiology

• Powell et al. AmJRespirCritCareMed 2013 — Update in lung cancer and mesothelioma 2012

Clinical-NSCLC-ALK

• Gainor et al. ClinCancerRes 2013 — ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS an analysis of 1,683 patients with non-small

Clinical-NSCLC-Driver-Other

• Johnson et al. JClinOncol 2014 — Recent clinical advances in lung cancer management

Clinical-NSCLC-EGFR

• Lee et al. AnnOncol 2013 — Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with
• Martinez-Marti et al. AnnOncol 2017 — Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung
• Paz-Ares et al. AnnOncol 2017 — Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer overall survival
• Rolfo et al. CancerTreatRev 2014 — Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors
• Bronte et al. CritRevOncolHematol 2014 — Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment
• Sequist et al. JClinOncol 2008 — First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
• Kelly et al. JClinOncol 2015 — Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT) A randomized,
• Lee et al. JClinOncol 2015 — Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after
• Magnuson et al. JClinOncol 2017 — Management of brain metastases in tyrosine kinase inhibitor-naive epidermal growth factor receptor-mutant
• Haratake et al. JTOClinResRep 2020 — Optimizing sequential treatment with EGFR tyrosine kinase inhibitor with a simulation of the T790M mutation rate in
• Zhou et al. LancetOncol 2011 — Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell
• Lee et al. LancetOncol 2012 — First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL) a
• Rosell et al. LancetOncol 2012 — Erlotinib versus standard chemotherapy as first-line treatment for european patients with advanced EGFR
• Rosell et al. LancetRespirMed 2017 — Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF)
• OKane et al. LungCancer 2017 — Uncommon EGFR mutations in advanced non-small cell lung cancer
• Kobayashi et al. MolCancerTher 2017 — Characterization of EGFR T790M, L792F, and C797S mutations as mechanisms of acquired resistance to afatinib in lung
• Rosell et al. NEnglJMed 2009 — Screening for epidermal growth factor receptor mutations in lung cancer
• Maemondo et al. NEnglJMed 2010 — Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
• Soria et al. NEnglJMed 2018 — Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer
• Wu et al. NEnglJMed 2020 — Osimertinib in resected EGFR-mutated non-small-cell lung cancer
• Robichaux et al. Nature 2021 — Structure-based classification predicts drug response in EGFR-mutant NSCLC
• Asao et al. RespirInvestig 2019 — Resistance to molecularly targeted therapy in non-small-cell lung cancer
• Carnio et al. SeminOncol 2014 — Extending survival of stage IV non-small cell lung cancer

Clinical-NSCLC-HER2

• Friedlaender et al. NatRevClinOncol 2022 — EGFR and HER2 exon 20 insertions in solid tumours from biology to treatment

Clinical-NSCLC-ROS1

• Yu et al. ClinLungCancer 2019 — Multiple biomarker testing tissue consumption and completion rates with single-gene tests and investigational use of